Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 11/20 | 0.51 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.48 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.48 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.48 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.48 |
| ▸ | LCK | P06239 | 2/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | GSK3A | P49840 | 1/20 | 0.46 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | KIT | P10721 | 1/20 | 0.44 |
| ▸ | GCK | P35557 | 1/20 | 0.43 |
| ▸ | RAF1 | P04049 | 2/20 | 0.43 |
| ▸ | BRAF | P15056 | 2/20 | 0.43 |
| ▸ | TNF | P01375 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4718731 | 0.95 | MAPK14 (0.49) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL4721112 | 0.88 | MAPK14 (0.47) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL4715838 | 0.88 | MAPK14 (0.48) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL4718921 | 0.87 | GCK (0.43) | MAPK14MAPK13MAPK9LCKSRC | |
| SCHEMBL4718949 | 0.85 | MAPK14 (0.52) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL4716379 | 0.84 | SLC2A1 (0.55) | KITRAF1BRAF | |
| SCHEMBL4717470 | 0.84 | MAPK14 (0.51) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL4714370 | 0.84 | FLT3 (0.45) | MAPK14MAPK13MAPK9LCKSRC | |
| SCHEMBL4717742 | 0.82 | LCK (0.43) | MAPK14LCKSRCBRAF | |
| SCHEMBL4718541 | 0.82 | KDR (0.49) | MAPK14MAPK9LCKSRCSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1737463-B1 | PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2008-12-03 | — | — | EP | claimed |
| EP-1737463-B1 | PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2008-12-03 | — | — | EP | disclosed |
| US-20080108608-A1 | Pyrimidines With Tie2 (Tek) Activity | ASTRAZENECA AB (SE) | 2008-05-08 | — | — | US | disclosed |
| EP-1737463-A1 | PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | AstraZeneca AB (SE) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005060970-A1 | PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108608-A1 | Pyrimidines With Tie2 (Tek) Activity | TIE1, TEK, TEKT1 | MAPK14 2983/4885MAPK13 2414/4885MAPK12 1933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.